CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Cryoablation, Radiofrequency Ablation, and Laser Ablation for Treatment of Chronic Rhinitis

Policy governs coverage determinations for cryoablation, radiofrequency ablation, and laser ablation to treat chronic rhinitis for Blue Cross Blue Shield - Rhode Island members.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyCryoablation, Radiofrequency Ablation, and Laser Ablation for Treatment of Chronic Rhinitis

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateJan 11, 2022

Next Review DateN/A

Key ActionPrior authorization is not applicable per this policy; verify benefits and coverage in the member's plan documents.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Not coveredMedicare Advantage stance

Not medically necessaryCommercial products stance

K190356Clarifix 510(k)

K192471RhinAer 510(k)

C9771, 30999, 31299Procedure codes referenced

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Determinations

Coverage stance

Coverage determinations

Medicare Advantage: Cryoablation, radiofrequency ablation, and laser ablation for chronic rhinitis (allergic or nonallergic) is not covered because evidence is insufficient to determine effects on health outcomes.

Commercial Products: Cryoablation, radiofrequency ablation, and laser ablation for chronic rhinitis (allergic or nonallergic) is considered not medically necessary because evidence is insufficient to determine effects on health outcomes.

Benefits may vary by group and contract. Refer to the member's Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for the specific terms of coverage, including any applicable non-covered or not medically necessary benefits.

For Commercial products, cryoablation, radiofrequency ablation, and laser ablation for chronic rhinitis (allergic or nonallergic) is considered not medically necessary because the evidence is insufficient to determine the effects of these technologies on health outcomes.

Coding

Referenced HCPCS/CPT codeHCPCS

C9771

Nasal/ sinus endoscopy, cryoablation tissue(s) and/or nerve(s), unilateral or bilateral nasal

Unlisted CPT procedure codes recommendedCPT

30999	Unlisted procedure, nose
31299	Unlisted procedure, accessory sinuses

Relevant ICD-10-CM codesICD-10

J30.0	Vasomotor rhinitis
J30.2	Other seasonal allergic rhinitis
J30.1	Allergic rhinitis due to pollen
J30.5	Allergic rhinitis due to food
J30.89	Other allergic rhinitis
J30.81	Allergic rhinitis due to animal (cat) (dog) hair and dander
J30.9	Allergic rhinitis, unspecified
J31.0	Chronic rhinitis

Provider Actions & Billing Notes

Prior Authorization

Prior authorization not applicable — verify member benefits

Prior authorization is not required under this policy. Providers should still verify benefits and coverage for the member's specific plan before scheduling or billing the service.

Note

Clinical pathway context — ablation as an alternative to medical therapy

Medical management is the standard of care for chronic rhinitis; ablation therapies (cryoablation, radiofrequency, laser) are described as an alternative when medical therapy is considered or insufficient.

Documentation Required

Benefit verification — consult member documents

Confirm coverage details, exclusions, and member-specific plan provisions by referring to the member's Benefit Booklet, Evidence of Coverage, or Subscriber Agreement prior to treatment.

Background

Ablation therapies — including cryoablation, radiofrequency ablation, and laser ablation — are proposed as alternatives to medical management for patients with chronic rhinitis. These procedures aim to reduce rhinitis symptoms by modulating autonomic input to the nasal mucosa, with patient-reported symptom relief and quality-of-life measures used to assess response. However, medical management remains the standard of care, and the current evidence is considered insufficient to establish consistent health outcome benefits for ablation approaches, which informs the restrictive coverage position in this policy.

Definitions

Ablation therapy — definition and context

DefinitionAblation therapy includes cryoablation (cryosurgical ablation, cryosurgery, or cryotherapy), radiofrequency ablation, and laser ablation intended to modulate autonomic input to the nasal mucosa to reduce rhinitis symptoms.

PurposeProposed as an alternative to medical management for patients with chronic rhinitis symptoms by reducing nasal antigen responses and vascular hyperreactivity.

Clinical contextMedical management remains the standard of care; ablation is considered for patients refractory to medical therapy as a less invasive option compared with procedures like vidian neurectomy.

Outcome measuresPrimary outcomes for assessing treatment response are patient‑reported symptoms and quality‑of‑life measures; radiologic and endoscopic scores may provide supportive information.

Clarifix / RhinAer — regulatory status